

Utilization of Sepsis Advisor Software Clinical EMR Tool Reduces Mortality in High-Risk Septic Patients

Yana Puckett*, Theophilus Pham and Steven Brooks

Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX, USA

*Corresponding Author: Yana Puckett, Department of Surgery, Texas Tech University Health Sciences Center, Lubbock, TX, USA. Received: November 16, 2020; Published: December 15, 2020

Abstract

Study Type: Retrospective study.

Level of Evidence: Level II

Background: Sepsis is the leading cause of death in U.S hospitals. Our institution implemented a Sepsis Advisor Software (SAS) that allows physicians to place orders quickly based on Surviving Sepsis Campaign guidelines (SSC). We hypothesize that use of the SAS tool results in decreased mortality in septic patients.

Methods: Electronic Medical Records were analyzed from 1/2016 to 3/2017, at a University Level I Trauma Center, for cases of sepsis defined by postoperative ICD-10 code A41, J18.9, N39.0 for age range 18 - 89. The cases were divided into two groups; sepsis advisor software used (SASu) and not used (noSAS). Independent t-test and Chi-Square test compared demographics, mortality, LOS, and treatment rapidity between the groups. Binary logistic regression analysis adjusted for severity of illness and mortality.

Results: 2,461 patients were diagnosed with sepsis between 1/2016 and 3/2017. SAS was used on 266 (10.81%). Antibiotics were administered within 3 hrs for 167 (62.78%) of SASu patients, compared with only 976 (44.46%) of noSAS patients (p = 0.0001). The total charges and cost were significantly higher among SASu patients compared to noSAS patients. After adjusting for age, BMI, risk of mortality, and severity of illness (SOI), SASu patients were 79% less likely to die if their SOI was Grade III or IV OR = 0.219; 95% CI (0.164 - 0.487), (P = 0.005); and 87.5% less likely to die if their risk of mortality was either Grade III or IV OR = 0.125; 95% CI (0.07 - 0.222), (P = 0.02).

Conclusion: Utilization of SAS at our hospital is associated with increased compliance with SSC and confers a mortality benefit in septic patients with high-risk of mortality and SOI.

Keywords: Sepsis; Antibiotics; Infection

Introduction

Sepsis is the leading cause of hospital mortality with more than 1.6 million cases diagnosed in the U.S each year [1]. Sepsis is the body's physiological response to bloodstream or tissue infection results in life-threatening organ dysfunction. Sepsis-related admissions account for \$24 billion healthcare dollars spent per annum, making it the most expensive admitting diagnosis in the United States [2]. Additionally, it is a leading cause of mortality and readmission, prompting a 62% readmission rate within 30 days [3]. Surgical patients account for nearly $\frac{1}{3}$ of sepsis cases and has 39% mortality rate in emergent cases and 30% of elective cases [4].

Citation: Yana Puckett., et al. "Utilization of Sepsis Advisor Software Clinical EMR Tool Reduces Mortality in High-Risk Septic Patients". EC Clinical & Medical Case Reports 4.1 (2021): 01-07.

Onset of sepsis may be rapid and devastating in the absence of efficient treatment. Prompt identification of sepsis is crucial, as mortality increases by 8% for every hour of treatment delay. Conversely, rapid diagnosis and treatment early after sepsis onset dramatically improves outcomes [5]. The Surviving Sepsis Campaign (SSC) guidelines were created in an effort to help physicians quickly identify patients with probable sepsis and recommend the appropriate treatment in an efficient manner. SSC guidelines are updated regularly in accordance with evidence-based literature.

Although the 2016 SSC guidelines remove most "early goal-directed therapy" (EGDT) endpoints described in prior editions and advocate for patient-specific tailoring of hemodynamic therapy, strong recommendations for standardized care are still promoted, including: (1) Identification of sepsis and prompt source control intervention, (2) Empiric IV antibiotic administration within 1hr, (3) Resuscitation with 30 ml/kg crystalloid fluids within the first three hours, with additional fluids guided by reassessment of hemodynamic status, to a target mean arterial pressure (MAP) of 65mmHg and also normalizing lactate. Utilization of SSC guidelines has a proven mortality benefit when medical practitioners implement the guidelines as soon as sepsis is detected [5].

Our institution implemented an interactive Sepsis Advisor Software (SAS), enabling a "one stop" computer screen location for review of sepsis-related data (vital signs, culture results and lab values including WBC, lactate, renal function) and also order sets for additional tests, labs, or evidence-based empiric antibiotic regimens per organ system. We hypothesize that the SAS would increase compliance with SSC guidelines, and use of the SAS for patients would result in decreased mortality compared to patients for whom the SAS was not utilized.

Methods

Data from the institutional sepsis committee was retrospectively collected from electronic medical records on all patients with a diagnosis of sepsis, severe sepsis, and septic shock. The sepsis and trauma committee exists at our institution to maintain database on all sepsis patients in an effort to improve care and outcomes for these patients. The sepsis and trauma committee database included information on whether or not the SAS tool was utilized. Data was analyzed from January 2016 to March 2017. Sepsis was defined by postoperative ICD-10 code A41, J18.9, N39.0 for age range between 18 - 89 for all hospital patients with a diagnosis of sepsis based on ICD-10 code designation listed above. Demographics as well as variables included in SSC guidelines bundle were abstracted. Patients were dichotomized into two groups: SAS utilized (SASu) and SAS not utilized (noSAS). Information was distributed during grand rounds at our hospital on the utility of the SAS tool during its implementation into our EMR system. In addition, a hospital-wide email was sent out with detailed information and instructions on the use of the SAS tool. However, during the study period, it was up to the discretion of the ordering physician on whether or not they wanted to use the SAS tool in treating septic patients

Outcome variables included amount of fluid administered, timing of antibiotics, timing of serum lactate, serum lactate level, length of stay, mortality, cost, and charges. Outcomes were compared between the two groups. IBM SPSS Statistics for Windows, Version 22.0 software was used to perform statistical analysis. Chi-square was used to compare outcomes for categorical variables. ANOVA and independent t-test were used to compare continuous variables. P-values of less than 0.05 were at the level at which variables were considered to be statistically significantly different.

A binomial logistic regression was used to adjust for confounding variables in predicting mortality for the variables of age, BMI, initial lactate level on admission, risk of mortality, and severity of illness. The variables chosen for logistic regression were variables that were used to indicate severity of sepsis in patients. These were also the variables most frequently mentioned in the Surviving Sepsis Campaign.

Citation: Yana Puckett., et al. "Utilization of Sepsis Advisor Software Clinical EMR Tool Reduces Mortality in High-Risk Septic Patients". EC Clinical & Medical Case Reports 4.1 (2021): 01-07.

Results

A total of 2,461 patients were admitted with a diagnosis of sepsis between January 2016 and March 2017, of these, SAS was used on 266 (10.81%). The age and BMI of patients was not statistically different between two groups. SASu patients had a higher risk of mortality and severity of illness grade (p < 0.0001). Antibiotics were administered within the first 3 hrs for 167 (62.78%) of SASu patients, while it was administered within 3 hours for only 976 (44.46%) of noSAS patients (p = 0.0001) (Table 2). Total charges, payments and cost were all significantly higher in SASu patients when compared to noSAS patients. Length of stay, age, BMI and fluid volume given were not significantly different between the two groups.

	SAS Used (n = 266)	NO SAS (n = 2195)	P-Value
	Mean (SD)	Mean (SD)	
Age	60.89 (17.745)	58.29 (17.68)	0.993
BMI	27.89 (12.97)	27.92 (15.68)	0.656
Payer Status	% [n]	% [n]	0.008
Medicare	62.41% [166]	50.30% [1104]	
Medicaid	10.15% [27]	13.17% [289]	
Private Insurance	15.79% [42]	22.19% [487]	
Self-Pay	11.65% [31]	14.35% [315]	
Risk of Mortality Score			0.0001
Grade I	0.75% [2]	1.00% [22]	
Grade II	3.38% [9]	11.94% [262]	
Grade III	12.03% [32]	18.86% [414]	
Grade IV	50.38% [134]	38.86% [853]	
Severity of Illness Grade			0.0001
Grade I	0	1.00% [22]	
Grade II	7.89% [21]	18.27% [401]	
Grade III	42.85% [114]	35.62% [782]	
Grade IV	48.49% [129]	42.73% [938]	

Table 1: Demographics.

*Chi-Square test used for categorical variables; **Independent t-test for continuous variables.

Total charges, payments, and cost were higher in SASu patients. Totals charges were \$24,762.90 higher in SASu patients (P = 0.002). Total cost was \$6,377.94 higher in SASu patients (P = 0.008). Total payment was \$4,025.76 higher (P = 0.016) in SASu patients. Overall, payment was nearly 20% higher in the SASu group (Table 2).

Fluids were more likely to be administered within 1 hour in 69.92% in SASu patients versus 62.60% in noSAS patients (P = 0.05). Additionally, fluids were more likely to be accurately dosed (i.e. 30 mg/kg) in SASu patients 43.23% vs. 31.11% (P < 0.0001) in noSAS patients. Antibiotics were more likely to be administered within 3 hours of presentation in SASu patients compared to noSAS patients (62.78% vs 44.46%) (P < 0.0001) (Table 2).

Mortality was similar between the two groups (14.66% vs 14.67%; P = 0.997) (Table 2), however, after adjusting for age, BMI, risk of mortality, and severity of illness, SASu patients were 79% less likely to die if their illness severity was Grade III or IV OR = 0.219; 95% CI (0.164 - 0.487), (P = 0.005); and 87.5% less likely to die if their mortality risk was either Grade III or IV OR = 0.125; 95% CI (0.07 - 0.222), (P = 0.02).

	SAS Used (n = 266)	NO SAS (n = 2195)	P-Value
	% [n]	% [n]	
Mortality	14.66% [39]	14.67% [322]	0.997
	Mean (SD)	Mean (SD)	
Total Charges (\$)	126421.25 (202399.26)	101658.35 (173340.00)	0.002
Total Payments (\$)	19850.20 (32389.01)	15824.44 (29681.07)	0.016
Total Cost (\$)	30474.24 (56174.02)	24096.30 (50534.76)	0.008
LOS (Days)	11.14 (13.05)	9.9 (10.8)	0.025
1 st Lactate Level	2.56 (1.8)	2.4 (2.1)	0.8
2 nd Lactate Level	1.73 (1.72)	1.36 (2.2)	0.25
Fluid Volume Given	1722.11 (1373.36)	1542.53 (1429.14)	0.922
Fluid Volume Given ml/kg	22.31 (16.43)	19.82 (18.44)	0.362
	%[n]	% [n]	
Fluids Administered Within 1 Hour	69.92% [186]	62.60% [1374]	0.05
Fluids Administered 30 mg/kg	43.23% [115]	31.11% [683]	0.0001
Antibiotics Administered Within 3 Hours of Presentation	62.78% [167]	44.46% [976]	0.0001
Antibiotics Administered Within 1 Hour of Presentation	8.27% [22]	7.61% [167]	0.328
Length of Stay Less than 1 Day	3.38% [9]	2.55% [56]	0.912

Table 2: Outcomes.

*Chi-Square test used for categorical variables; **Independent t-test for continuous variables.

Omnibus Tests of Model Coefficients was found to be statistically significant, p < 0.0001, Chi-Square of 53.04, DF 9. The Nagelkerke R Square was 0.398, which shows that 39.8% of variability of our dependent variable (mortality) was explained by the independent variables of (age, BMI, risk of mortality, and severity of illness). The Homer and Lemeshow Test was not statistically significant (p = 0.989).

Discussion

Sepsis is a leading cause of morbidity, mortality, expense, and accounts for between one-third to one-half of all hospital deaths [6]. Updated consensus guidelines from the Surviving Sepsis Campaign emphasize early identification of sepsis, prompt antibiotic administration, aggressive source control, appropriate antibiotic stewardship, and patient-specific tailoring of hemodynamic therapy with frequent reassessment to achieve improved outcomes [5]. Order sets, checklists, reminder cards, and EMR decision support have all been shown to increase compliance with SSC guidelines and improve sepsis associated mortality [7]. Texas Tech's University Medical Center developed the Sepsis Advisor Software (SAS) tool to increase physician compliance with current evidence-based SSC guidelines for improved care of the septic patient. The SAS tool can be seen in figure 1 and 2.

The SAS significantly improved timely empiric antibiotic administration at our university hospital. Antibiotics were administered within the first 3 hours for 167 (62.78%) of SASu patients, compared with only 976 (44.46%) of the patients without the tool (p = 0.0001).

Citation: Yana Puckett., et al. "Utilization of Sepsis Advisor Software Clinical EMR Tool Reduces Mortality in High-Risk Septic Patients". EC Clinical & Medical Case Reports 4.1 (2021): 01-07.

Utilization of Sepsis Advisor Software Clinical EMR Tool Reduces Mortality in High-Risk Septic Patients

iscem Advisor®. Interdisciplinary Se	psis Managemen	t Advisor							* Selectio	
Evaluate Patient Risk Select Recomm	endations 2 Docum	ient and Sigr								
Evaluate Patient Risk										
4 Current State										
This patient shows signs of: SIRS		V Last /								
Allergies All Encounters				evant Results 72 hours				Antibiotic Orders Last 90 Days		
No Known Allergies				tate, arterial	1.3	MMOL/L	12/00/2017 15-0	ciprofloxacin + D5W		Last Dose: 12/01/2017 10:
			V/8			89 K/ut.	12/01/2017 05:0	cprofloxacin 400 mg RTU IVP8	400mg, ONE TIME, IV	Last Dose: 11/30/2017 10:
				atinine		ng/d.	12/01/2017 05:01	fluconazole	400mg, q245, 7178	Last Dose: 11/30/2017 22:
			Lact	ctic Acid Level	2.4	MMOL/L	11/29/2017 22:3	metroNIDAZOLE	500mg, gib, TVP8	Last Dose: 12/01/2017 15:
Microbiology						Vital Signs				
Last 6 Results Culture	Collection DI/Tm	Result			Status	Last 3 Resu	Ats Latent	Previous		Previous
Sputum Culture	11/29/2017	POS	Klebsiella pneumoniae su	ubsp pneumoniae	Completed	Tem	98.5 11/29/2017 18:30	98.4 11/25/20	7 18-05	98.4 11/28/2017 17:57
Urine Culture	11/29/2017	REVIEW			Completed		R 156 13/01/2017 21:50	452 12/01/201	7 20:17	457 12/01/2017 18:00
Blood Bacterial Culture	11/29/2017	REVIEW			InProcess		P 1141/154 12/01/2017 18-00	136/151 12/		131/149 13/01/2017 16:00
Blood Bacterial Culture	11/29/2017	REVIEW			InProcess	NA	P 76 13/01/2017 18-00	73 12/01/2017		70 12/01/2017 16-00
Culture: Wound w/GS	62/18/2016	REVIEW			Completed		R 16 12/01/2017 21:10	17 12/01/2017		16 12/01/2017 18:00
Culture: Body Fluid w/Gram Stain	02/36/2036	POS			Completed					 Relations many
						🗆 Mag	o less than or equal to 65 or SBP less	than of equal to 90		
4 Suspected Infection Sources										
Select up to two (2) suspected source.	es. Select 'Unclear I	(not neutro	senic)' if more than two	io (2) sources are su	uspected for br	oader coverag	е.			
Bone Infection/Osteomyeitis			E Feb	brile Neutropenia			0	Skin/Soft Tissue Infectio	o*	
C. Officie			🗔 Joi	int Infection/Septic Ar	irthritis"			Urinary Source*		
Catheter and Device Infection										
				eningitis				Wound Infection* Source Unclear (Not Net	(tropenic)	
Endocardts* Intra-Abdominal Source* OCI (Cockcroft-Gault): 70.87 kg upruces	,				Selec	t Recommence		Wound Infection* Source Unclear (Not Ne		used in the achieve is a Measure
Intra-Abdominal Source* OCI (Cockcroft-Gault): 70.87 kg IL/10/208 Estimated Greatine Geannee	,			eningitis			tations	Source Unclear (Not Ne	The weight being	used in the advisor is a Measur
CCI (Cockcroft-Gault): 20.87 kg 12/11/201	,			eningitis	OR	mally adjust dos	tations	Source Unclear (Not Ne	The weight being	used in the advisor is a Heasur
Intra-Abdominal Source* OCI (Cockcroft-Gault): 70.87 kg Internet Estimated Orastine Clarance: @Normal Dose	,			eningitis	OR		tations		The weight being	used in the advisor is a Heasun
COC (Coduruh Gautz: 70.87 kg Coc (Coduruh Gautz: 70.87 kg Coc Costune Classine Classine: - Citional Dong Cisingle Dois A ALERGES_SECTION_LEL	7			eningitis	OR	mally adjust dos	tations	Source Unclear (Not Ne	The weight being	used in the advisor is a Heasun
COG (Coldorad Source* COG (Coldorad Source* Commended Creations Clearance: - @tiomal Doing Costing Cost AULERGES_SECTION_LIBL Alogas Al Documents	,			eningitis	OR	mally adjust dos	tations	Source Unclear (Not Ne	The weight being	used in the advicer is a Measure
CG (Codcorth Gault): 70.87 kg Issues Estimated Crastines Caratines Conserves	,			eningitis	OR	mally adjust dos	tations	Source Unclear (Not Ne	The weight being	used in the advisor is a Measur
bits-Abdomial Source* OCI (Coductri-Garkh; 20.87 kg, Lanum Estimated Crastines Gersnets #ichomal Dange Single Date A LECOSES_SECTION_LBL Adapase Altimates Ite Scional Adapase Altimates A Scional Regis A Autobiot: Recommendations				eningitis	OR	mally adjust dos	tations	Source Unclear (Not Ne	The weight being	used in the advisor is a Measur
CCI (Coderoft-Garlt) 70.87 kg annum Einmeide Oratine Gearance - Einmeide Oratine Gearance - Citioned Dang Single Goose 4.4420645, SICCON-LIDL Annum Ito Known Alerges 24.4420645 Recommendations Personnal - Communications	ected			engts eurona*	⊂R. ○ 0	małły adjust dos Wysis Patient: [tations e using:	Source Unclear (Not Ne	The weight being	used in the advicer is a Monur
bits-Abdemial Source* OCI (Colcord-Galk); 70.87 kg Lanuar Estimated Crastines Clearance Rithormal Dong Single Date A LECOSC_SECTION_LEL Alloges A Colcole_Sections Posturinis Posturinis Posturinis Community legared 1963 Allog Community legared 1963 Al	ected s primary therapy, ur	less significan		engts eurona*	⊂R. ○ 0	enally adjust dos lialysis Patient: [containing aztrec	e uange	Source Unclear (Not Ne	The weight being	and in the advisor is a Measur
bits-Abdemial Source* CCI (Colorent Gault): 70.87 kg. course Estimated Outstrine Gearance: - Rhoman Dange Single Dase 4 ALEROSE, SECTION, LBL Adapas Mitinautes Ro Konne Margis 4 Abdok: Recommendations Presimona: - Genumer kapanet Presimona: - Genumer kapanet Presimona: - Genumer kapanet Presimona: - Genumer kapanet Brancobole: - Presimona: - Genumer kapanet Coloren Adapase Addok Brancobole: - Residen data on adapase Addok Brancobole: - Residen d	ected s primary therapy, ur rolise over 3 bit		Pred t allergy or recently used	eemona* leumona*	⊂R. ○ 0	enally adjust dos waysis Patients [ontaning astree 0 a	Estions e ung: pour f potent ha history of sever stressom 7 potent has history of sever	Source Unclear (Not Ne)))))))))))))))))))	The weight being allergy.	
CCI (codcord-Garlt): 70.87 kg servers Entrace Crastine Cerance: - Entrace Crastine Cerance: - Entrace Costine Cerance: - Entrace Cerance: -	ected s permany therapy, un release over 30 min Torkase over 30 min Torkase over 30 min (DeOt	ETORING ADV	Pre	eemona* leumona*	⊂R. ○ 0	enally adjust dos waysis Patients [containing actives v	e ung:	Source Unclear (Not Ne	The weight being i altergy,	
CCG (colcord-Gault) 70.87 kg torrun Entrace Cratine Cestione Cestione Entrace Cratine Cestione Control Contro	ected a permany therapy, ur vision over 10 min forkan over 30 min Table, bridge over 10 min Table, bridge over 10 min	ETORING ADV	Pre	eemona* leumona*	⊂R. ○ 0	enally adjust dos waysis Patients [containing actives v	Estions e ung: pour f potent ha history of sever stressom 7 potent has history of sever	Source Unclear (Not Ne	The weight being i altergy,	
CCI (coderardi Source' CCI (coderardi Gatti) 70.07 kg assume Estimated Chattine Cesance: - Code Continue Cesance: - Code Continue Cesance: - Code Continue Cesance: - Code Continue Cesance: - Code Cesance	ected a primary therapy, ur folkes over 30 min. (Moto folkes over 30 min. (Moto Table, Johns over 30 min folkes over 30 min. orden over 31 min.	ETOAING ADVI	Pre- t allergy or recently used (1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	eemona* leumona*	⊂R. ○ 0	enally adjust dos waysis Patients [containing actives v	e ung:	Source Unclear (Not Ne	The weight being i altergy,	
CCG (colcord-Gault) 70.87 kg torrers Entrace Cratines Cestions Cestions Entrace Cratines Cestions Control Control Cestion Control Cestion Control Cestion Control Cestion Control Cestion Ces	ected s primary therapy, ur folse over 10 min folse over 10 min 1048, bridge over 10 min 1048, bridge over 10 min 1048, bridge over 10 min 1048, bridge over 10 min	ETORING ADVI	t allergy or recently used	energta www.mena*	⊂R. ○ 0	enally adjust dos waysis Patients [containing actives v	e ung:	Source Unclear (Not Ne	The weight being i altergy,	
CCI (Cockerd): 20.07 kg .exem Enhance Costance Cesance: - Control Costance Cesance: - Costance Costance Cesance: - Costance Costance Cesance: - Costance Cesance: - Costance Cesance: - Alternet: Cesance: - Cesance: - C	ected s primary therapy, ur folse over 10 min folse over 10 min 1148, Johan over 10 min 1148, Johan over 10 min 1148, Johan over 10 min 1148, Johan over 10 min	ETORING ADVI	t allergy or recently used	energta www.mena*	⊂R. ○ 0	enally adjust dos waysis Patients [containing actives v	e ung:	Source Unclear (Not Ne	The weight being i altergy,	
CCI (colorenti Gaute) 20.07 kg assume Estimate Coastine Cesance - Coastine Coastine Cesance - Coastine Coastine Cesance - Coastine Cesance - Coastine Cesance - Coastine Cesance - Altered Second Altered Particular Community Acaded - HELA Sup Particular Community Acaded - HELA	ected s primary therapy, ur folse over 10 min folse over 10 min 1148, Johan over 10 min 1148, Johan over 10 min 1148, Johan over 10 min 1148, Johan over 10 min	ETORING ADVI	t allergy or recently used	energta www.mena*	⊂R. ○ 0	enally adjust dos waysis Patients [containing actives v	e ung:	Source Unclear (Not Ne	The weight being i altergy,	
bits-Abdomid Source* OCI (colcord-Gall); 70.87 kg tourse Enneed Castine Cleance: - Commol Door Casting Door Autorial Control Lab. Anges About Control Lab. Anges About Control Lab. Anges Control Control Lab. Anges Control Control Lab. Control Con	ected permay therapy, un observe 10 min. Dollan over 10 min. Perfage over 11 min. perfage over 11 min. Perfage over 10 min. (NOI Diffuse over 10 min. (NOI	ETORING ADVI	t allergy or recently used	energta www.mena*	⊂R. ○ 0	enally adjust dos waysis Patients [containing actives v	e ung:	Source Unclear (Not Ne	The weight being i altergy,	
CCI (Cockerd): 20.07 kg .exem Enneted Costine Geranes: - Generation Costanes: - Generation Costanes: - Generation Costanes: - Costanes: - Costanes: - Automatical In Science: - Costanes: - Automatical Parameterization: - Costanes: - Costane	ected permay therapy, un observe 10 min. Dollan over 10 min. Perfage over 11 min. perfage over 11 min. Perfage over 10 min. (NOI Diffuse over 10 min. (NOI	ETORING ADVI	t allergy or recently used	energta www.mena*	⊂R. ○ 0	enally adjust dos waysis Patients [containing actives v	e ung:	Source Unclear (Not Ne	The weight being i altergy,	
	ected permay therapy, un observe 10 min. Dollan over 10 min. Perfage over 11 min. perfage over 11 min. Perfage over 10 min. (NOI Diffuse over 10 min. (NOI	ETORING ADVI	t allergy or recently used	energta www.mena*	⊂R. ○ 0	enally adjust dos waysis Patients [containing actives v	e ung:	Source Unclear (Not Ne	The weight being i altergy,	
CCI (Cockerd): 20.07 kg .exem Enneted Costine Geranes: - Generation Costanes: - Generation Costanes: - Generation Costanes: - Costanes: - Costanes: - Automatical In Science: - Costanes: - Automatical Parameterization: - Costanes: - Costane	ected permay therapy, un observe 10 min. Dollan over 10 min. Perfage over 11 min. perfage over 11 min. Perfage over 10 min. (NOI Diffuse over 10 min. (NOI	ETORING ADVI	t allergy or recently used	energta www.mena*	⊂R. ○ 0	enally adjust dos waysis Patients [containing actives v	e ung:	Source Unclear (Not Ne	The weight being i altergy,	
	ected permay therapy, un observe 10 min. Dollan over 10 min. Perfage over 11 min. perfage over 11 min. Perfage over 10 min. (NOI Diffuse over 10 min. (NOI	ETORING ADVI	t allergy or recently used	energta www.mena*	⊂R. ○ 0	analy adjust dos alyas Patenti [ontaining actree y	Estions a unity [noinin fightent has history of sever before the state of the sever before the sever fight has a set before the sever fight has a sever fight has a set before the sever fight has a sever fight	Source Unclear (Not Ne	The weight being i altergy,	fan eel norto-
Intra-Abdomnal Source* COI (colcord-Gault) 20.87 kg servers Entrace Coastine Ceastines Commol Zong Channel Zong Channel Zong Channel Zong Autoroact, server-Intra- Autoroact, server- Auto	ected pprmay therapy, ut who near the bolas over H who in the Sing Sing H was bolas over H was provide a server H	ETORING ADVI	t allergy or recently used	In the operation of the	() a c	ontaning attree	e emp: me emp: pram f potent has history of sever strenum: pram	Source Unclear (Not Ne	The weight being i altergy,	das and monter
CCI (Cockerd): 20.07 kg : seven Etimized Costinie Classines :- Commo Dange Channel Dang Change Construct Classines :- Alternates Recommendations Plannendia Community Acaded - MidA.Sug Plannendia Community Acaded - MidA.Sug PlannendiaCommunity Acaded - MidA.Sug PlannendiaCog: active Academ Acaded - MidA.Sug PlannendiaCog: active Academ Acaded - MidA.Sug PlannendiaCog active Academ A	ected pprmay therapy, ut who near the bolas over H who in the Sing Sing H was bolas over H was provide a server H	ETORING ADVI	t allergy or recently used	energta www.mena*	() a c	ontaining attree	Eatloor e ump oun f patent has hatory of sever telesoum 2 to roll, solve delay be refubliced in the selection of severe PT with INR _ pate, the PT with INR _ pate, the PT with INR _ pate, the	Source Unclear (Not Ne	The weight being i altergy,	fan eel norto-
CCI (Colcord, Garlet) 20.87 kg Issuers Extended Crastine Cleances - Extended Cl	ected pprmay therapy, ut who near the bolas over H who in the Sing Sing H was bolas over H was provide a server H	ETORING ADVI	t allergy or recently used	In the operation of the	() a c	ontaining attree	Easterner e earling: source fighteent has hadory of annexes seconding: a prime has hadory of annexes seconding: a prime has been sources and seconding: a mysics prime has been prime has been sources prime h	Source Unclear (Not Ne	The weight being i altergy,	das pel norte: December Ordered 120(2017) Ordered 120(2017)
CCI (Cockerd): 20.07 kg : seven Etimized Costinie Classines :- Commo Dange Channel Dang Change Construct Classines :- Alternates Recommendations Plannendia Community Acaded - MidA.Sug Plannendia Community Acaded - MidA.Sug PlannendiaCommunity Acaded - MidA.Sug PlannendiaCog: active Academ Acaded - MidA.Sug PlannendiaCog: active Academ Acaded - MidA.Sug PlannendiaCog active Academ A	ected percent Memory and the percent Memory and Memory and Annual Annual Memory and A	ETORING ADVI	t allergy or recently used	In the operation of the	() a c	antak adut do Antaria antarna atterio v	Eatloor e ump oun f patent has hatory of sever telesoum 2 to roll, solve delay be refubliced in the selection of severe PT with INR _ pate, the PT with INR _ pate, the PT with INR _ pate, the	Source Unclear (Not Ne	The weight being i altergy,	das and monter

Figure 1 and 2: Sepsis advisor software tool.

Fluids were also more likely to be administered within 1 hour in 69.92% in the SASu group versus 62.60% in the noSAS group (P = 0.05). The fluid administered was also more likely to be accurately dosed (i.e. 30 mg/kg) in SASu patients 43.23% vs. 31.11% (P < 0.0001) in noSAS patients. Interestingly, the first and second lactate levels did not differ significantly between the two groups, possibly underscoring the importance of the initial time to fluid bolus.

Total charges, payments, and cost were all significantly higher among SASu patients when compared to noSAS patients. The SAS tool was used in more severely septic patients, who may have required additional treatment, resulting in the higher total cost for these patients. Length of stay, age, BMI and fluid volume given were not found to be significantly different between the two groups.

Citation: Yana Puckett., et al. "Utilization of Sepsis Advisor Software Clinical EMR Tool Reduces Mortality in High-Risk Septic Patients". EC Clinical & Medical Case Reports 4.1 (2021): 01-07.

After adjusting for age, BMI, admission lactate level, mortality rick, illness severity, SASu patients were 79% less likely to die if their severity of illness was Grade III or IV and 87.5% less likely to die if their risk of mortality was either Grade III or IV. This marked mortality improvement may underscore that the SSC guidelines are most important in the sickest patients. Of note, the SAS tool was not used in patients with Grade I Illness Severity and was used in only 21 (4.98%) of Grade II illness severity patients. It would seem that physicians had a sense for which patients were at higher risk and chose to use the tool in this sicker population. Although the tool was used in sicker patients, overall use of the tool was poor at only less than 11%.

It is important to note that despite the improvement in early antibiotic administration with SAS tool, even in patients with SAS utilization, antibiotics were not administered within 3 hours in almost 40% of patients. Some possible barriers that would lead to the late administration of antibiotic to patients in both groups include: delays in processing the order; delays at the level of the physician putting in the order; delay in the pharmacist sending the antibiotics IV; delay in the administration of the antibiotic by the nursing staff. It is assumed that these barriers were present in both the SASu and noSAS groups, so they would not confound the outcomes.

Limitations to this study included retrospective review and a lack of SAS tool usage in patients with low risk of mortality score and severity of illness grade. Additionally, the tool did not address or encourage the use of repeated hemodynamic status assessments. While the tool provided organ system specific evidence-based empiric antibiotic choices, it did not encourage or track antibiotic stewardship in the form of proper de-escalation and timing. The use of SAS was left to the discretion of the ordering physician which is why it was only used on 10.81% of the postoperative septic patients. There was also a lack of identification of alternate confounding factors such as time to source control. Intensive care unit status was not accounted for between SASu and noSAS group which could explain why SAS patients were more expensive and had a greater severity of illness and risk for mortality.

Further studies should address additional secondary outcome variables such as hospital length-of-stay (los), intensive care unit LOS, discharge disposition (i.e. home versus skilled nursing). Increased usage of the SAS tool in lower grade illness severity patients might reveal whether the SSC guidelines are just as important in these lower-acuity septic patients. The length of time to set up the SAS as well as the cost associated can also be measured to see how reproducible this would be in different hospital settings.

Conclusion

This study adds to the literature endorsing SSC guideline adherence for improved mortality in septic patients. Additionally, use of the SAS tool improved physician compliance to SSC guidelines, resulting in improved mortality in high mortality risk and illness severity septic patients.

Author Contribution

Theophilus Pham: literature search, data analysis, writing, revisions.

Yana Puckett: data collection, data analysis, data interpretation, writing, revision.

Steven Brooks: study design, writing, revision.

Bibliography

- 1. Liu V., *et al.* "Hospital Deaths in Patients With Sepsis From 2 Independent Cohorts". *The Journal of the American Medical Association* 3120.1 (2014): 90-93.
- 2. Torio CM and MPH Moore B. "National Health Spending In 2014: Faster Growth Driven By Coverage Expansion And Prescription Drug Spending". *Health Affairs* 35.1 (2016): 150-160.
- 3. Fingar K and Washington R. Trends in Hospital Readmissions for Four High-Volume Conditions, 2009-2013". *Statistical Brief* 196 (2015): 1-17.
- 4. Scerbo Michelle H and Laura J Moore. "Early Management of Sepsis, Severe Sepsis, and Septic Shock in the Surgical Patient." Common Problems in Acute Care Surgery". *Springer International Publishing* (2017): 71-93.
- 5. Rhodes A., et al. "Surviving Sepsis Campaign". Critical Care Medicine 45.3 (2017): 486-552.
- Howell MD and Davis AM. "Management of Sepsis and Septic Shock". *The Journal of the American Medical Association* 317.8 (2017): 847-848.
- 7. Damiani E., *et al.* "Effect of Performance Improvement Programs on Compliance with Sepsis Bundles and Mortality: A Systematic Review and Meta-Analysis of Observational Studies". *Plos One* 10.5 (2015): e0125827-e0125824.

Volume 4 Issue 1 January 2021 All rights reserved by Yana Puckett., *et al.*